Health Care • Medical/Dental Instruments
$17.58 ▼ -0.27
(-1.51%)
MKT CAP: $955.8M • VOL: 1.29M
52W L $9 52W H $33
BBNX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $100.3M | $65.1M | $12.0M |
| YoY Revenue Growth % | +53.9% | +442.9% | — |
| Gross Profit | $55.5M | $35.9M | — |
| Gross Margin % | 55.4% | 55.1% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$71.7M | -$45.3M | -$35.9M |
| Operating Margin % | -71.5% | -69.5% | -80.0% |
| Net Income (GAAP) | -$73.2M | -$54.8M | -$44.1M |
| EBITDA (Normalized) | -$67.4M | -$42.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$50.9M | -$48.3M | -$32.4M |
| Capital Expenditures (CapEx) | $5.3M | $3.4M | — |
| Free Cash Flow (FCF) | -$56.2M | -$51.7M | -$32.4M |
| FCF Margin % | -56.1% | -79.3% | -80.0% |
| Return on Invested Capital (ROIC %) | -22.1% | -45.0% | — |
| Cash & Short-Term Equivalents | $31.6M | $30.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $287.6M | -$245.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BBNX.